|
Market Closed -
Nasdaq
23:00:00 25/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 113.90 USD | -1.15% |
|
+1.29% | +69.24% |
| 09-18 | Halozyme Prices $1.3 Billion Convertible Senior Notes Offering | MT |
| 09-16 | Halozyme Therapeutics Plans $1.05 Billion Offering of Convertible Notes | MT |
| Market Cap | 12.93B 11.34B 10.71B 9.76B 18.28B 1,239B 18.41B 128B 49.66B 633B 48.54B 47.49B 2,034B | P/E 2026 * |
15.8x | P/E 2027 * | 12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 14.27B 12.52B 11.83B 10.78B 20.18B 1,368B 20.32B 142B 54.82B 699B 53.58B 52.42B 2,246B | EV / Sales 2026 * |
7.7x | EV / Sales 2027 * | 6.46x |
| Free-Float |
98.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| HALO | Delayed | |
CBOE
| HALO | Real-time | |
|
Tradegate
| RV7 | Real-time | |
|
Mexican S.E.
| HALO * | End-of-day quote | |
|
Boerse Muenchen
| RV7 | Real-time | |
|
Börse Stuttgart
| RV7 | Delayed | |
|
Deutsche Boerse AG
| RV7 | Delayed | |
|
Berne S.E.
| RV7 | End-of-day quote | |
|
Borsa Italiana
| 1HALO | End-of-day quote | |
|
Xetra
| RV7 | Delayed |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | -1.15% | ||
| 1 week | +1.29% | ||
| Current month | +6.96% | ||
| 1 month | +4.19% | ||
| 3 months | +56.81% | ||
| 6 months | +80.11% | ||
| Current year | +69.24% |
| 1 week | 110.95 |  | 116.84 |
| 1 month | 103.47 | | 116.84 |
| Current year | 61.32 | | 116.84 |
| 1 year | 61.22 | | 116.84 |
| 3 years | 32.83 | | 116.84 |
| 5 years | 29.85 | | 116.84 |
| 10 years | 8.18 | | 116.84 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 63 | 06/01/2014 |
David Ramsay
DFI | Director of Finance/CFO | 61 | 01/05/2013 |
| Director of Finance/CFO | - | 08/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 59 | 28/03/2013 |
Helen Torley
BRD | Director/Board Member | 63 | 06/01/2014 |
| Chairman | 61 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/16/26 A | Sell | Director | -18,996 | 0.0167% | ||
| 9/11/26 A | Exercice | Chief Executive Officer | 60,000 | 0.0529% | ||
| 9/1/26 A | Free | Director | 2,939 | 0.0026% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.15% | +1.29% | +53.98% | +192.88% | 12.93B | |
| +0.54% | +1.30% | +91.73% | +40.57% | 367B | |
| +0.78% | +3.97% | +27.12% | -14.58% | 66.89B | |
| +0.24% | +0.49% | -1.88% | -16.04% | 7.54B | |
| -1.30% | -2.32% | -27.85% | -11.12% | 4.38B | |
| -1.33% | -2.37% | -37.20% | +5.00% | 4.07B | |
| -4.23% | +2.14% | -30.63% | -11.67% | 3.02B | |
| -1.46% | +1.57% | -9.58% | +49.37% | 2.48B | |
| -2.18% | -0.66% | -22.30% | -33.51% | 1.91B | |
| +4.31% | +9.45% | +24.17% | +93.64% | 1.85B | |
| Average | -0.59% | +1.25% | +6.75% | +29.45% | 47.21B | |
| Weighted average by Cap. | +0.35% | +1.60% | +75.78% | +34.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.85B 1.63B 1.54B 1.4B 2.62B 178B 2.64B 18.38B 7.12B 90.76B 6.96B 6.81B 292B | 2.05B 1.8B 1.7B 1.55B 2.9B 197B 2.92B 20.33B 7.88B 100B 7.7B 7.53B 323B |
| Net income | 869M 762M 720M 656M 1.23B 83.27B 1.24B 8.62B 3.34B 42.54B 3.26B 3.19B 137B | 1.07B 937M 885M 806M 1.51B 102B 1.52B 10.59B 4.1B 52.29B 4.01B 3.92B 168B |
| Net Debt | 1.34B 1.18B 1.11B 1.02B 1.9B 129B 1.91B 13.33B 5.16B 65.8B 5.05B 4.94B 211B | 320M 280M 265M 241M 452M 30.62B 455M 3.17B 1.23B 15.64B 1.2B 1.17B 50.28B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/09/26 | $113.90 | -1.15% | 1,958,390 |
| 24/09/26 | $115.22 | +2.47% | 3,172,136 |
| 23/09/26 | $112.44 | -2.34% | 2,702,793 |
| 22/09/26 | $115.13 | +3.30% | 4,151,542 |
| 21/09/26 | $111.45 | -0.89% | 2,876,988 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
